产品展示

Anti-TGFB1 antibody [EPR21143] (ab215715) was developed by Abcam using patented rabbit monoclonal antibody technology and is validated for use in IHC-P and WB.

Anti-TGF beta 1 antibody [EPR21143] (ab215715) was first used in a scientific publication in 2019 and has been cited over 223 times in peer reviewed journals. It's performance in Western blot in human, mouse and rat samples is trusted by the scientific community.

Abcam's high quality manufacturing and validation processes ensure Anti-TGF beta 1 antibody [EPR21143] (ab215715) has high sensitivity and specificity alongside high lot-to-lot consistency and reproducibility.

The specificity of Anti-TGF beta 1 antibody [EPR21143] (ab215715) has been confirmed by Western Blot testing in TGF beta 1 knockout A549 cells (ab269509).

Anti-TGF beta 1 antibody [EPR21143] (ab215715) has 6 independent reviews from customers.

Anti-TGFB1 antibody [EPR21143] (ab215715) specifically detects TGF beta 1 (UniProt ID: P04202; Molecular weight: 29kDa) and is sold in 100 µL and 1 mL selling sizes.

Conjugation-ready, carrier free format available for antibody clone EPR21143 - ab229856.

Antibody clone EPR21143 is also available pre-conjugated to a variety of labels for your convenience - Alexa Fluor® 647, Alexa Fluor® 488, Alexa Fluor® 555 (ab281316, ab313729, ab313730).

TGF-β1 (Transforming Growth Factor Beta 1) is a cytokine that suppresses immune cell activity, aiding tumor growth and immune evasion. It also regulates the tumor microenvironment, contributing to fibrosis and tissue remodeling.

Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

This product is a recombinant monoclonal antibody, which offers several advantages including:

• - High batch-to-batch consistency and reproducibility
• - Improved sensitivity and specificity
• - Long-term security of supply
• - Animal-free batch production

For more information, read more on recombinant antibodies.

Patented technologyOur RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

What are the advantages of a recombinant monoclonal antibody?This product is a recombinant monoclonal antibody, which offers several advantages including:

• - High batch-to-batch consistency and reproducibility
• - Improved sensitivity and specificity
• - Long-term security of supply
• - Animal-free batch production